Adocia Shares Fall as Lilly Terminates Diabetes Alliance
By Cormac Sheridan
Tuesday, July 30, 2013
Shares in Adocia SAS plunged by as much as 45 percent Tuesday on news that Eli Lilly and Co. has pulled out of an alliance to develop an ultra-fast-acting insulin analogue for diabetes based on Adocia's Biochaperone formulation technology.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.